Royalty Report: Drugs, cardiac, Biotechnology – Collection: 255948


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • cardiac
  • Biotechnology
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 255948

License Grant
This Agreement is for the Transfer and assign from Licensor to Licensee for all right, title, and interest to the patent and related clinical information covering LiprostinTM.
License Property
The pharmaceutical drug candidate is LiprostinTM for improving the effectiveness of current standard-of-care treatments related to endovascular interventions in the treatment of peripheral artery disease (PAD). LiprostinTM has completed FDA Phase I and three Phase II clinical trials, and we are evaluating several contract research organizations ('CRO') for completion of our U.S. Food and Drug Administration ('FDA') protocol for Phase III.
Field of Use
The clinical stage patented pharmaceutical brand LiprostinTM is focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).
Peripheral artery disease is a narrowing of the peripheral arteries serving the legs, stomach, arms and head. (“Peripheral” in this case means away from the heart, in the outer regions of the body.) PAD most commonly affects arteries in the legs. Both PAD and coronary artery disease (CAD) are caused by atherosclerosis.

IPSCIO Record ID: 7466

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
Field of Use
Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

IPSCIO Record ID: 530

License Grant
Licensor will grant Licensee an exclusive (even as to Licensor), worldwide, fully-paid, perpetual license (with the right to sublicense) under Licensor’s interest in any Collaboration Technology jointly owned by Licensor and Licensee necessary or useful to make, have made, import, use, offer for sale and sell Development Candidates (and corresponding Collaboration Products), subject to Article 15, for indications other than those which Licensor retains rights hereunder, and products other than Collaboration Products.
License Property
Collaboration Products refer to research, develop and commercialize gene-based products incorporating the VEGF gene for the treatment of coronary artery disease and peripheral vascular disease.  VEGF is a protein that stimulates the formation of new blood vessels and improves blood flow.
Field of Use
Field shall mean the research, drug discovery and development collaboration aimed at therapeutic agents useful for Gene Therapy-based induction of angiogenesis and for the first two years of the Research Program shall include all clinical indications; provided, thereafter the Field shall be limited to the treatment of coronary artery disease (CAD) and/or peripheral vascular disease (PVD) and/or those other specific clinical indications selected by Licensor pursuant to Section 2.5 below.

IPSCIO Record ID: 248329

License Grant
The Canadian Licensor hereby grants to Licensee of Netherlands within the Field of Use, and Licensee accepts, the exclusive worldwide right, sublicense and privilege under the Licensor Licensed Rights to use the Licensor Licensed Technology and to use, manufacture, distribute and sell Licensed Products.  Licensee shall sponsor the research Project as defined in the Collaborative Research Agreement between Licensor and University and, for that purpose, Licensee and Licensor entered into Heads of Agreement effective August 1, 2000.
License Property
Project means the project description entitled “LPL Gene Therapy for LPL Deficiency”, which is attached to the Collaborative Research Agreement, including any amendments thereto which the Parties and University may mutually agree to, from time to time, of the Collaborative Research Agreement.

The scientific collaboration is in the area of LPL gene therapy in humans including all research and development required for establishing a successful clinical LPL gene therapy protocol.

Description of Technology
U.S. 5,658,729 – Lipolipase Mutation 291, Implication for Coronary Artery Disease
U.S.  SN 08/737,954 – Recombinant Viruses Preparation and use thereof in Gene Therapy

Field of Use
Field of Use means gene therapy being the treatment of a disease caused by the malfunction of a gene, by transduction of cells of the organism with the normal gene or genetically altered gene.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 289243

License Grant
The Licensor of Sweden grants an exclusive, worldwide license under the Licensed Licensor Patent Rights and Licensor Know-How to develop, make, use, import, export, offer for sale and sell, and to have developed, made, used, imported, exported, offered for sale and sold, the Licensed Products, with the right to grant sublicenses.
License Property
Licensor has developed the Compound as a therapeutic for the cardiovascular market.

The Compound means the Milano variant of Apolipoprotein A-1.

Licensed Product means any pharmaceutical product including the Compound as its active ingredient the manufacture, use or sale of which would infringe one of the issued, valid unexpired claims or one of the pending claims contained in the Licensor Patent Rights in any country or involves use of the Licensor Know-How.

Field of Use
The field of use is the development of novel anti-atherogenic therapies.

Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. Initially, there are generally no symptoms. When severe, it can result in coronary artery disease, stroke, peripheral artery disease, or kidney problems, depending on which arteries are affected.

IPSCIO Record ID: 5858

License Grant
The Licensor has granted the Licensee a non-revocable and exclusive worldwide license including the right to sublicense to third parties to the patents necessary to develop and commercialize drug candidates in which Cardio Vascu-Grow is the active ingredient. As a part of that agreement, Licensor will provide technical development services to us for the development and regulatory approvals of our drug candidates, including but not limited to, lab work, testing and production of our drug candidates in which Cardio Vascu-Grow is the active ingredient for clinical trials, all as directed by us.
License Property
We are working closely with an affiliated company, Cardio, pursuant to a joint patent and technology sharing agreement, to manufacture human fibroblast growth factor-1 (Cardio Vascu-Grow) for Cardio’s ongoing clinical trials.

Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients.  Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).

Issued US Patents
1. U.S. 6,268,178 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;” and
2. U.S. 6,642,026 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.”
3. U.S. 6,773,899 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides”;
4. U.S. 6,794,162, entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;”
Pending US Patent Applications 1.. U.S. 10/649,480 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;” published as US Patent Application No. US 2004/0115769

Field of Use
Cardio Vascu-Grow™ stimulates the growth of new blood vessels, a biological process termed “angiogenesis”. This growth factor is being tested in a wide variety of human diseases that would benefit from increased angiogenesis including coronary artery disease, stroke, and peripheral vascular disease of the legs and wound healing.

IPSCIO Record ID: 372578

License Grant
The original agreement between the Licensor of Sweden and Licensee is for selective inhibition ADP compound known as Cangrelor.

This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.

License Property
Cangrelor, a potent intravenous adenosine diphosphate-receptor antagonist, significantly reduced the rate of ischemic events, including stent thrombosis, during PCI without increasing severe bleeding when compared with clopidogrel, according to a late-breaking trial presented here.

CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.

Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.

Field of Use
The field of use is in patients undergoing percutaneous coronary intervention or PCI.  Cangrelor is used during percutaneous coronary intervention (PCI) for reducing the risk of heart attacks.  Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.

IPSCIO Record ID: 368507

License Grant
The Licensor, an individual, hereby grants to Licensee an exclusive license to practice under the Licensed Patents and use the licensed information, with the right to grant sublicenses, to make, have made, use, sell, have sold, offer to sell, import or export Licensed Products within the field in the licensed territory (the License).
License Property
The intellectual property portfolio for 2NTX-99 includes an issued U.S. patent and a pending Patent Cooperative Treaty submission relating to its composition of matter, multiple methods of manufacturing, and method of use in treating a variety of atheroclerotic-thrombotic pathological conditions.

U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled “Compound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.

Field of Use
2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.

Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).

IPSCIO Record ID: 279309

License Grant
Licensor grants to the Licensee of Puerto Rico an exclusive license, with the right to sublicense, under the Licensor Compound Patents, Other Licensor Patents and Licensor Know-How, to research, develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory.

Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.

License Property
Licensor is engaged in manufacturing, research and development of pharmaceutical products and is currently engaged in the development of AGI-1067.  

Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.

AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

Field of Use
Licensee is engaged in the research, development, manufacture and marketing of pharmaceutical products.  AGI-1067 is designed to benefit patients with coronary heart disease (CHD), which is atherosclerosis of the blood vessels of the heart.   Atherosclerosis is a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls.

IPSCIO Record ID: 117698

License Grant
The parties co-promote INTEGRILIN in the United States and share any profits or losses. Outside of the United States, the Swiss Licensee markets INTEGRILIN exclusively.

With this amendment the Parties desire to modify their agreement to address such issue of sales allocation, and also with respect to the allocation of regulatory responsibilities in Canada, the manufacture and supply of Integrilin Product in Canada, and to set forth certain understandings regarding a Phase III clinical trial for Integrilin Product in the setting of acute myocardial infarction or AMI.

License Property
INTEGRILIN(R) (eptifibatide) Injection, is the only drug approved for use in both acute coronary syndromes and angioplasty procedures.
Field of Use
This agreement is for the pharmaceutical industry.
INTEGRILIN is indicated for the treatment of patients with an acute coronary syndrome and patients who undergo angioplasty procedures. The acute coronary syndrome indication includes patients with unstable angina and non-Q-wave myocardial infarction, whether they receive medical treatment or undergo angioplasty.

Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.

Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis.

IPSCIO Record ID: 359108

License Grant
Canadian Licensor granted Licensee the sole, exclusive, irrevocable license to patented nanotechnologies for use with any drugs including cannabinoids,  to develop and optimize a proprietary nanoformulation of pharmaceutical cannabidiol, designed to avoid first-pass metabolism and improve bioavailability, for the treatment of heart failure.
License Property
Nanotechnologies are designed to improve solubilization, pharmacokinetics, and drug targeting of lipophilic drugs. Nanotechnologies is the use of matter on an atomic, molecular, and supramolecular scale for industrial purposes.

Cannabidiol is a non-psychoactive molecule with broad therapeutic potential in the treatment of chronic inflammatory disease including heart failure.

Field of Use
The license to patented nanotechnologies is for use with any drugs or classes of drugs currently used or developed in the future to diagnose or treat heart failure and/or any cardiovascular disease and/or cardiopulmonary disease and/or cardiac arrhythmias.

Field of use to treat cardiovascular disease, cardiopulmonary disease, and cardiac arrhythmias.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.